Genticel, a French biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus, today announces that the US Food and Drug Administration (FDA) has cleared Genticel’s Investigational New Drug application to conduct in the US a phase 1 clinical study of GTL001 in patients infected with HPV 16 and/or 18, the two HPV types responsible for 70{20b543310651bf6f3679f07daa0e532ca50e05ab066d8bcfc12d35f979f65272} of cervical cancer cases.

Taken from:
Genticel’s GTL001 phase 1 clinical study of HPV therapeutic vaccine granted FDA clearance